R&D Harnessing the cell's own degradation machinery, with Benedi... Benedict Cross, Chief Technology Officer at PhoreMost, discusses targeted protein degradation.
R&D Future glances: More change, more tech, more harmonisation According to Deloitte’s 2026 Life Sciences Outlook Survey, the life sciences sector might be becoming increasingly borderless, but only 41% of responding biopharma and medtech executives fe
R&D Why drug delivery is biotech’s overlooked challenge – and it... Delivery innovations don’t just improve outcomes – they reshape the entire therapy ecosystem.
R&D The case for engagement in medical training: Why interactive... Trainees need to be maximally empowered to connect the dots before they enter hospitals or labs.
R&D On CB1s as an alternative to GLP-1s, with Punit Dhillon In a new pharmaphorum podcast, Punit Dhillon, CEO of Skye Bioscience, discusses CB1 inhibitor antibodies in the obesity space.
R&D Sponsored Thermo Fisher Scientific on the value of an integrated appro... In a new sponsored video, Thermo Fisher Scientific’s Alberto Fernández discusses the company's Accelerator Drug Development solution.
News Major trial launched to explore GLP-1 benefit in dementia A $100m trial has been launched to see if lifestyle changes coupled with GLP-1 agonists or similar incretins can reduce the risk of dementia.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
